Article

Akorn ophthalmic gel given approvable letter

Akorn Inc. has received an FDA approvable letter for an ocular topical anesthetic 3.5% (Akten Ophthalmic Gel).

Buffalo Grove, IL-Akorn Inc. has received an FDA approvable letter for an ocular topical anesthetic 3.5% (Akten Ophthalmic Gel).

The letter identified several minor deficiencies that have been addressed in previous submissions, according to the company, and the deficiencies need to be rectified before final approval is granted.

No additional clinical data were required for the remaining response submitted to the FDA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.